Soma Gold Valuation
Is 8PR1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 8PR1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 8PR1's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 8PR1's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 8PR1?
Key metric: As 8PR1 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 8PR1's PS Ratio? | |
|---|---|
| PS Ratio | 0.7x |
| Sales | CA$84.20m |
| Market Cap | CA$55.27m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1x |
| Enterprise Value/EBITDA | 3.1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 8PR1's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.6x | ||
IBU IBU-tec advanced materials | 0.7x | 19.2% | €33.3m |
DLX Delignit | 0.3x | 10.2% | €24.4m |
BNN BRAIN Biotech | 1.2x | 8.5% | €68.8m |
2HRA H&R GmbH KGaA | 0.1x | 2.7% | €127.3m |
8PR1 Soma Gold | 0.7x | n/a | €55.3m |
Price-To-Sales vs Peers: 8PR1 is expensive based on its Price-To-Sales Ratio (0.7x) compared to the peer average (0.6x).
Price to Sales Ratio vs Industry
How does 8PR1's PS Ratio compare vs other companies in the European Metals and Mining Industry?
| 35 Companies | Price / Sales | Estimated Growth | Market Cap |
|---|---|---|---|
| 35 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Sales vs Industry: 8PR1 is good value based on its Price-To-Sales Ratio (0.7x) compared to the European Metals and Mining industry average (0.7x).
Price to Sales Ratio vs Fair Ratio
What is 8PR1's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.7x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 8PR1's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Arkema
€5.7b
Manufactures and sells specialty chemicals and advanced materials worldwide.
V1S
€74.95
7D
-3.9%
1Y
-19.5%
Tokuyama
JP¥196.7b
Produces and sells various chemical products in Japan.
TBT
JP¥16.60
7D
5.7%
1Y
14.5%
Ecora Resources
UK£162.5m
Operates as a natural resource royalty and streaming company in Australia, North and South America, Europe, and internationally.
HGR
UK£0.76
7D
1.5%
1Y
-28.3%